The generic liraglutide option for Victoza was approved by the FDA on December 23, 2024. The generic is only approved to be used to improve blood sugar control in type 2 diabetes (as an adjunct to diet and exercise), but it may also lead to some weight loss....
Learn about FDA-approved weight loss injections like Wegovy and Zepbound, and weight loss drugs such as Contrave, to support your weight management goals.
The present drugs available for the treatment of obesity and metabolic syndrome are few in number and limited in efficacy. This chapter reviews the drugs approved by the US Food and Drug Administration (FDA) to treat obesity, drugs approved by the FDA for other indications than weight loss, ...
Mounjaro belongs to a class of drugs called GLP-1 agonists that includes Saxenda and Wegovy, which are already FDA-approved for weight loss in people who are either overweight with at least one weight-related medical problem or obese. Dr. Amanda Velazquez, director of obesity medicine at Ced...
Dr. Alexandra Sowa, an obesity medicine specialist and author of the new book “The Ozempic Revolution” shares the pros and cons of using GLP-1 medications for weight loss. 2 months ago FDA approves weight loss drug Zepbound to treat sleep apnea ...
The present drugs available for the treatment of obesity and metabolic syndrome are few in number and limited in efficacy. This chapter reviews the drugs approved by the US Food and Drug Administration (FDA) to treat obesity, drugs approved by the FDA for other indications than weight loss, ...
Currently, the drug is only approved bythe Food and Drug Administration (FDA)for the long-term treatment of obesity (with or without Type 2 diabetes) in children who are at least 12 years old. DOCTORS DRAW ATTENTION TO SAFETY ISSUES ASSOCIATED WITH POPULAR WEIGHT-LOSS DRUGS ...
Proponents of Ozempic microdosing claim you'll reap the drug's benefits with fewer side effects. But is taking small doses of GLP-1 agonists safe and effective for weight loss?
The history of FDA-approved weight loss drugs is a recent one; in 1999, the FDA approved a pancreatic and gastric lipase inhibitor, orlistat (Xenical), followed by approvals in 2012 and 2014 for phentermine/topiramate-ER (Qysmia; Vivus) and naltrexone/bupropion (Contrave; Currax),...
Is the hope that the U.S. Food and Drug Administration (FDA) might approve these drugs for the treatment of opioid use disorder? If GLP-1 agonist drugs are already approved for human use, does that fast-track things? Bunce: Yes. If we demonstrate that these medications are efficacious in...